No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BDX240621P225000
- 1.47
- -1.84-55.59%
15min DelayClose May 31 16:00 ET
2.30High1.47Low
2.30Open3.31Pre Close6 Volume293 Open Interest225.00Strike Price1.12KTurnover20.23%IV-3.64%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry1.47Time Value100Contract SizeAmericanOptions Type-0.2309Delta0.0285Gamma157.27Leverage Ratio-0.0792Theta-0.0251Rho-36.32Eff Leverage0.1612Vega
Intraday
- 5D
- 1D
News
Express News | Bd : Goldman Sachs Initiates Coverage With Buy Rating; Price Target $274
Piper Sandler's Actionable Trading Ideas: 3 Positive, 3 Negative
Becton Dickinson Initiated at Buy by Goldman Sachs
Becton Dickinson Initiated at Buy by Goldman Sachs
Express News | Goldman Sachs Initiates Coverage On Becton Dickinson With Buy Rating, Announces Price Target of $274
Here's Why Becton Dickinson (NYSE:BDX) Can Manage Its Debt Responsibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
BD's (BDX) FDA-Approved Test to Offer Wider Testing Access
Becton, Dickinson and Company BDX, popularly known as BD, recently received the FDA’s approval for the use of self-collected vaginal specimens for human papillomavirus (HPV) testing when cervical specimens cannot otherwise be obtained.
Comments
$Becton Dickinson & Co(BDX.US$ GAME OVER stock.
Despite a dip in earnings, Becton Dickinson's high P/E ratio persists due to anticipated robust future growth, outpacing the broader market. Investors' confidence in the company's future earnings is high, indicating the share price is unlikely to drop significantly soon.
$Becton Dickinson & Co(BDX.US$ BD Receives FDA 510(k) Clearance for Potentially Transformative Fingertip Blood Collection Device
2
Dr. Silverman's extensive experience and zeal for innovation, evidence generation, clinical development, medical safety, and compliance is predicted to boost BD's innovation pipeline and foster improved, personalized care.
Market sentiment towards Becton, Dickinson and Company shows no major shift in the past year. However, the rise in total shareholder return hints at a growing positivity.
Read more